A highly efficient copper-catalyzedasymmetricaddition of terminal alkynes to isatins has been developed. In the presence of a catalytic amount of copper iodide and a chiral phosphine ligand, the reaction gave the corresponding chiral 3-alkynyl-3-hydroxyindolin-2-ones in high yields with high enantioselectivity. This methodology has a broad substrate scope, and the synthetic utility of the present
simple way to the homocoupling of tertiary halides induced by photocatalysis. This method features mild reaction conditions, excellent functional group tolerance, high yields, low photocatalyst loading and successful application to the highly sterically hindered systems. On the basis of the reaction results, a novel stable-radical-induced homocoupling reaction mechanism has been proposed.
palladium-catalyzed nondirected fluorinated olefination was developed. The oxalyl amide ligand greatly improved the yield of the reaction. A wide variety of isatin derivatives were well tolerated and yielded the corresponding products in moderate to good yields. Various fluorinatedolefins were also compatible. The application and synthesis of bioactive compounds such as a Metisazone derivative highlight the synthetic
[EN] N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS<br/>[FR] DÉRIVÉS DE N-[(AMINOSULFONYL)PHÉNYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDÈNE)-HYDRAZINECARBOTHIOAMIDE POUR LE TRAITEMENT DU CANCER ET DE TROUBLES IMMUNOLOGIQUES
申请人:ISTANBUL UNIV REKTORLUGU
公开号:WO2017099695A1
公开(公告)日:2017-06-15
N-[(aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-hydrazinecarbothioamide derivatives of the following formula (III) for treating cancer and immunological disorders. R5, R6 and R7 are each independently selected from hydrogen and a sulfonamide group, provided that at least one of R5, R6 or R7 is a sulfonamide group. The substituents R1 to R4 are each independently either hydrogen or one of the substituents defined in the claims.